QT Imaging : Investor Presentation | May 2026

Published: 2026-05-13 10:26:10 ET QTI

Published on 05/13/2026 at 10:26 am EDT

NASDAQ:QTI

Quantitative Transmission Imaging

Breast Acoustic CT Scanner

May 2026

Disclaimer

FORWARD LOOKING STATEMENTS

Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "has the potential to", "believe", "may", "will", "estimate", "continue", "anticipate", "intend", "expect", "should", "would", "plan", "predict", "potential", "seem", "seek", "future", "outlook", and similar expressions that indicate or predict future events or trends that are not statements of historical matters. These forward looking statements include, but are not limited to, the potential impact on existing medical technology, the company's technology, including, the evolution of the Company into a scalable imaging platform combining proprietary hardware, advanced image reconstruction software, and AI-powered clinical decision tools to address the growing need for precision in breast health and the performance of software enhancements, product offerings, including QTI Cloud Platform and SaaS pricing model, business prospects, revenue, client adoptions, commercialization, including in Saudi Arabia and UAE, timing of reimbursement codes, projections of market opportunity, regulatory approvals and statements regarding estimates and forecasts of other financial and performance metrics. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of QT Imaging Holdings' management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not circumstances intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. In addition, statements regarding the Company's products, technology, and market opportunity reflect the beliefs and opinions of QT Imaging Holdings' management on the relevant subject as of this Presentation. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of QT Imaging Holdings. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; risks related to the rollout of QT Imaging Holdings' business and the timing of expected business milestones; the demand for QT Imaging Holdings' products and services; the ability of QT Imaging Holdings to increase sales of its output products in accordance with its plans; issues that could arise with respect to the manufacture of QT scanners by CMSC; the desire of customers and service recipients to continue engaging QT Imaging Holdings; the effects of competition on QT Imaging Holdings' future business, changes in the Company's strategy, future operations, financial positions, and product development timeline. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging Holdings presently does not know or believes is immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging Holdings' expectations, plans or forecasts of future events and views as of the date of this Presentation. QT Imaging Holdings anticipates that subsequent events and developments will cause its assessments to change. However, while QT Imaging Holdings may elect to update these forward-looking statements at some point in the future, its specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing QT Imaging Holdings' assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

RISK FACTORS

An investment in our common stock involves a high degree of risk. The risk factors described below are not intended to be exhaustive and are not the only risks facing us. Additional risks not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and cash flows in future periods or are not identified because they are generally common to businesses. The occurrence of one of more of the events or circumstances described in these risk factors, along or in combination with other events or circumstances, could harm our business, financial condition, results of operations, and growth prospects. In such event, the market price of our common stock could decline, and you may lose all or part of your investment. The following should be read in conjunction with the respective consolidated financial statements of the Company, and the notes to the consolidated financial statements included therein. Risk factors include, but are not limited to:

We are a development-stage company with limited operating history and significant losses since inception which may make it difficult to evaluate prospects for our future viability and predict our future performance. We may never be able to effectuate our business plan or achieve any meaningful revenue or reach profitability.

We may not be able to successfully execute our business model.

We have a limited operating history. If we successfully commercially launch the QTI Breast Acoustic CT Scanner, as well as products under development that are cleared by the FDA and other regulatory agencies, and they do not achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business.

We may need to raise additional capital, which may not be available on favorable terms, if at all, and which may cause dilution to stockholders, restrict our operations or adversely affect our ability to operate our business.

Our ability to generate the amount of cash needed to pay interest and principal on any indebtedness and our ability to refinance all or a portion of our indebtedness or obtain additional financing depends on many factors beyond our control.

Our debt agreements contain restrictions that may limit our flexibility in operating our business.

We are highly dependent on the successful development, marketing and sale of our breast imaging device and on other products and product candidates which are still in the development stage.

Our Mission

Transforming Breast Health For Every Woman

At QT Imaging, we are redefining what's possible in breast imaging - delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short. Our goal is to replace outdated breast imaging workflows with the first scalable 3D safe imaging platform for dense breast diagnostics and precision breast oncology.

QT Imaging Transformation

$18M from NIH to develop supplemental imaging modality to resolve dense breasts

2012-2025

QTI becomes public on NASDAQ

Mar 2024

Raise

$18M PIPE

Oct 2025

Approval of Reimbursement Category III CPT Code

Feb 2026

2012

Company founded by John Klock, MD

2017

FDA

Clearance

Feb 2025

QTI gets delisted, public on OTC, QTIH

Jan 2026

Relisted on Nasdaq

The Pain and Why QT Imaging

Mammography misses cancers in

dense breasts / it is painful.

MRI is expensive / slow / uncomfortable

/ contract injection

Ultrasound is operator dependent

Workflow is fragmented

High anxiety / recall / attrition

QT Imaging has uniquely differentiated solution

Accurate diagnosis in dense breasts

Product is validated and FDA cleared

Commercial engine is now live

Reimbursement de-risks adoption

Financial inflection is imminent

AI / biomarkers provide upside

Accurate Imaging for Dense Breasts

Primary Screening

Today's Challenge:

Multi-step, patient anxiety and attrition prone process with high number of unnecessary biopsies

QT Imaging Solution:

Single step (Supplemental + Dx) patient friendly process, with potential to reduce unnecessary biopsies

Breast Density Confirmation

Supplemental Screening

Diagnostic

Imaging

HHUS or MRI

QT Imaging provides no radiation, no contrast, no compression imaging with no operator variability that requires less scheduling leading to less patient anxiety and attrition.

Biopsy via

QT Imaging Value Proposition

One-stop-shop supplemental

+ diagnostic imaging

No radiation, no compression, no contrast

Low recall, less anxiety

Operator independent

One test - multiple results

(MRI like Imaging)

Calcium visualization (DCIS + Ca, Density, Doubling, Cyst/Solid, Implant)

Biomarkers: reflection, speed of sound, attenuation & breast density measure (FGR)

Low recall, operator independence

biopsies

with 5 patients/day

Potential to reduce unnecessary

2.5 X more revenue per scan compared to mammography + handheld ultrasound

30% less annual labor cost -

nonspecialized personnel

Comparable siting costs and annual service

Reduced overhead with one-stop-shop

3-year investment recovery

FDA-cleared, patent protected breast imaging modality

Pain free, safe, no radiation or contrast

Inherently 3D quantitative, imaging modality, thus it's high

resolution, similar to MRI

Two independent sources of information:

Our Technology and Product

− CT-like configuration with ultrasound to acquire and reconstruct transmission images - unique biomarker, speed of sound

− Reflection images for high-resolution depiction of tissue interfaces, as well as improved lesion visualization (cancers have irregular, heterogeneous reflective signatures)

Reflection transducers

Transmission mode receiver

Overcomes operator dependence and lack of standardization associated with HHUS

Transmission mode transmitter

Quantitative Transmission Imaging Compared With MRI As Supplemental

PerfeQTion Imaging Center

Haverford, PA

Optimized Patient Experience

10-12 minutes per breast exam time

Quiet and comfortable (compared to MRI -

claustrophobia, coil pressure, noise, lengthy exams)

(compared to MRI Gadolinium)

Quantitative Imaging Platform

Enables AI and Biomarker Expansion

Deployment within QTI Cloud SaaS Integration via InteleShare's framework

Automated pipelines for image reconstruction, feature extraction, Probability of Cancer Map generation

Continuous learning from clinical data uploads and feedback loops

Unique quantitative data: Speed of Sound, Attenuation, Reflection, Nakagami parameters etc.

Early detection of malignancy using defined

quantitative thresholds

Therapy monitoring such as pathological complete response (pCR) prediction in neoadjuvant therapy

Personalized medicine, by correlating imaging biomarkers with genomic and histopathologic data

Automated lesion characterization and BI-RADS aligned standardization for consistent interpretation

Our Market, Why Now, and How It Fits In

QT Imaging's Technology Has the Opportunity to

Transform the Breast Imaging Market

CURRENT MARKET

Breast Imaging:

$6B MARKET (1)

FDA approved as supplemental

Layer Description

Total global opportunity

2025

Value

2030

Value

CAGR

NEW MARKET

SaaS Biomarkers:

$1B MARKET (3)

Move to personalized,

screening device for breast imaging

Aim to revolutionize current imaging paradigm, replacing mammography + ultrasound (handheld and automated), and freeing MRI scanners time

TAM

SAM

(dense-breast supplemental screening (4) + biomarkers (3))

Accessible reimbursed markets (U.S., OECD, Korea, Japan) (2)

$2.5B

$1.7B

$3.8B

$2.6B

8.5%

precision diagnostics

Move to personalized treatments with therapy guidance and monitoring

Imaging

Penetration

~10% SAM share by 2030

$18M

$200-250M

If we capture as low as 10% of cash only and reimbursed segments of addressable market, we are at $200M+ revenue scale.

https://www.futuremarketinsights.com/reports/automated-breast-ultrasound-system-market

https://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market $5.45B for 2024 with 8.9% CAGR.

https://www.archivemarketresearch.com/reports/breast-cancer-biomarkers-316622 13

FDA Density Disclosure Requirements

50%

50% of women between the ages of 40-74 in the

U.S. have dense breasts(1)

(3)

QTscan identified abnormalities in dense breasts that were not identified by x-ray mammograms(2)

Ray Mammogram

QTscan

"the new rule advises physicians and patients to consider breast density alongside other cancer risk factors when deciding whether additional screening is necessary"

- Hilary Marston,

CHIEF MEDICAL OFFICER, FDA

Breast Density on a Mammogram, Susan G. Komen

QTI Study | Dense Breast Mass Detection

"Mammograms Must Include Breast Density Information, New FDA Rule Says". Wall Street Journal

The Role of Ultrasound in Screening Dense Breasts. NCBI.

AI Adoption in Radiology and

Personalized Oncology/Biomarkers

Radiology is the leading specialty for clinical AI adoption

~30 to 48% of radiologists report active clinical AI use; adoption continues to accelerate across imaging workflows

Most FDA-cleared clinical AI tools are in radiology

Medical imaging remains the largest category of FDA cleared AI/ML enabled medical devices

AI is shifting from workflow support to diagnostic augmentation

AI tools increasingly assist with detection, prioritization, quantification, and structured reporting

Cloud delivered AI is becoming the preferred

deployment model

Institutions increasingly expect centrally updated, scalable software rather than on premise installs

Oncology is moving from one-size-fits-all treatment toward biomarker-guided therapy

Precision oncology increasingly relies on quantitative

biomarkers to personalize treatment selection and monitoring

Radiomics converts imaging into quantitative biomarkers

Imaging biomarkers can support diagnosis, prognosis, and treatment response prediction beyond visual interpretation

Breast cancer treatment increasingly requires earlier response assessment

Imaging biomarkers are being studied for early prediction of neoadjuvant therapy response and pathologic complete response

Standardized quantitative imaging platforms

are advantaged

Reproducible, inherently quantitative modalities are better suited for robust biomarker development than subjective/ operator dependent imaging

QT Imaging is uniquely positioned at the intersection of two major healthcare shifts:

Category III CPT Code Approval - X579T

Submitted on November 3, 2025

Approved by AMA in February 2026

Scheduled for release on July 1, 2026, with

an effective date of January 1, 2027

The new Category III code, X579T, represents a significant milestone in the clinical and commercial advancement of QT Imaging's technology, recognizing the distinct clinical service enabled by its radiation free, compression free, 3D breast imaging platform

Breast Cancer Screening Matrix: QT Imaging Sweet Spot

Risk Category

(Tyrer-Cuzick Lifetime Risk)

+ Breast Density

Typical Risk Profile Description

< 40 Years

≥ 40 Years

Low Risk (<12%)

(~20-30% of women)

No first-degree relatives with

breast cancer

No known pathogenic mutations No prior chest radiation

No high-risk breast lesions

Favorable reproductive/ hormonal profile

No routine imaging; breast awareness

Mammography beginning at 40-45; annual or biennial

Intermediate Risk (12-19.9%)

(~60-70% of women)

May have one second-degree relative

Common reproductive risk factors (early menarche, late first birth, etc.)

Dense Breasts

No known high-risk mutation

No strong clustering of early cancers

No routine imaging

Begin mammography at 40; annual or biennial depending on shared decision-making

High Risk (≥20%)

(~8-12% of women)

Known pathogenic mutation (e.g., BRCA1/2)

Strong family history

(multiple relatives, early-onset cases)

Dense Breasts

Prior chest radiation before age 30 High-risk lesions

(atypical hyperplasia, LCIS)

Annual breast MRI starting 25-30

Add mammogram at 30

Annual MRI + annual mammogram

Validation

NIH has awarded QT Imaging about

$18M

for new women's

imaging solution

Existing FDA clearance to offer an imaging modality for all patients above 18 years old

Received UAE regulatory approval

NIH $18M funding to generate a safe imaging

modality for women with dense breasts

Ongoing clinical studies at:

− Mayo Clinic

− Sunnybrook Cancer Center

− To start soon: Stanford

− In discussions: UCSF, Harvard

Category III code, X579T

Clinical Validation Across Screening and

Oncology Applications: Mayo Clinic - QTscan vs MRI

Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QTscan) with breast MRI for supplemental screening

Strong breast-level agreement with MRI: binary agreement between QTscan and MRI across 52 breasts

Comparable detection profile

All MRI-suspicious lesions were identified by QTscan

Disclaimer

QT Imaging Holdings Inc. published this content on May 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 14:25 UTC.